A blood clot is a gel-like mass of blood cells and proteins that forms when your body’s clotting system activates, either to seal a wound or, sometimes, inside a blood vessel where it can cause serious harm. The same mechanism that saves your life after a cut can trigger a heart attack, stroke, or pulmonary embolism when it fires in the wrong place or at the wrong time. Understanding how clots form, what tips the balance from protective to dangerous, and what treatments exist gives you a practical framework for recognizing risk and acting on it.
How a Blood Clot Forms
Clotting starts with a cascade of chemical reactions in your blood. When tissue is damaged, the injured cells release a substance called tissue factor, which kicks off a chain of enzyme activations. Each enzyme in the chain switches on the next, amplifying the signal rapidly until a key enzyme called thrombin is produced. Thrombin converts a dissolved protein in your blood, fibrinogen, into insoluble fibrin strands that weave together into a mesh, trapping blood cells and forming a solid plug over the wound.1PubMed. Blood coagulation Platelets, the tiny cell fragments that circulate in your blood, pile onto the site first and provide a scaffold that fibrin reinforces. The whole process can seal a small cut in minutes.
This is normal hemostasis, and it is essential. Without it, even a minor injury could lead to uncontrolled bleeding. The problem arises when the same cascade fires inside an intact blood vessel, building a clot (called a thrombus) that blocks blood flow to tissues that need it.
What Pushes Clotting From Helpful to Harmful
More than 150 years ago, the physician Rudolf Virchow identified three broad factors that promote abnormal clotting: changes in blood composition, damage to the vessel wall, and sluggish blood flow. Modern research has refined this framework but not replaced it. No single abnormality reliably predicts who will develop a dangerous clot; instead, it is typically the interaction of two or all three factors that tips the balance.2PubMed Central. Procoagulant activity in hemostasis and thrombosis: Virchow’s triad revisited
Consider atrial fibrillation, a common heart-rhythm disorder. It illustrates all three prongs at once: the irregular heartbeat causes blood to pool in the atria (slow flow), the walls of the atria undergo scarring and tissue changes (vessel wall abnormality), and clotting factors and platelet activity ramp up beyond normal levels (blood composition shift).3Heart. Atrial fibrillation and the prothrombotic state: revisiting Virchow’s triad in 2020 That combination makes atrial fibrillation one of the leading causes of stroke-producing blood clots.
Arterial Clots and Venous Clots Are Not the Same
People often talk about blood clots as if they are all alike, but the clots that form in arteries look and behave quite differently from those in veins. Arterial clots tend to form in areas where fatty plaque has narrowed and roughened a vessel wall. They are dense, packed mainly with fibrin and platelets, with relatively few red blood cells. Venous clots, by contrast, form in slower-moving blood and are dominated by red blood cells and fibrin, giving them a softer, redder appearance.4Scientific Reports. The distinctive structure and composition of arterial and venous thrombi and pulmonary emboli
This difference matters for treatment. Because arterial clots are platelet-heavy, antiplatelet drugs like aspirin are a frontline defense in heart attack and stroke prevention. Venous clots respond better to anticoagulants that target the fibrin-forming cascade. A clot that breaks loose from a deep vein and travels to the lungs, a pulmonary embolism, shares the composition of the venous clot it came from and is treated accordingly.
Causes and Risk Factors
Clotting risk is shaped by a mix of genetics, medical conditions, medications, and everyday circumstances. Some of these factors are modifiable, others are not, and having more than one multiplies the danger.
Inherited Clotting Disorders
Certain genetic mutations make the clotting cascade fire more easily. The two best-studied are the Factor V Leiden mutation and the prothrombin 20210A variant, both found almost exclusively in people of European descent.5PubMed. Factor V Leiden, prothrombin 20210A, methylenetetrahydrofolate reductase 677T, and population genetics Together, these two mutations account for roughly two-thirds of families identified with inherited thrombophilia.6Clinical Chemistry. Factor V Leiden and other coagulation factor mutations affecting thrombotic risk Carrying one of these variants does not guarantee you will develop a clot, but it raises baseline risk, especially when combined with other triggers like surgery, pregnancy, or long immobility.
There is an evolutionary dimension to this. The Factor V Leiden mutation emerged roughly 22,000 years ago and now appears in about 5 percent of people with European ancestry. While it increases the risk of venous clots, it historically offered survival advantages, including reduced blood loss during childbirth and improved iron stores, which may explain why natural selection preserved it.7PubMed. Human Evolution: Between Hemorrhage and Thrombosis
Cancer
Cancer is one of the strongest acquired risk factors for clotting. Tumor cells can release tissue factor and other substances that directly activate the clotting cascade, and they also trigger inflammatory signals that push the blood toward a clot-prone state.8PubMed Central. The hypercoagulable state of malignancy: pathogenesis and current debate Some cancers, particularly those of the pancreas, lung, and brain, carry an especially high clotting risk. The tumor cells release tissue factor into the bloodstream, which activates coagulation factors in a chain reaction that results in fibrin formation, the same mesh that seals a wound.9Heliyon. Pathogenesis and clinical monitoring of blood hypercoagulability in patients with malignant tumors For many cancer patients, a blood clot is actually the first sign that a malignancy exists.
Hormonal Factors
Estrogen-containing hormonal contraceptives raise clotting risk by increasing the liver’s production of several coagulation proteins. The synthetic estrogen found in most combined birth-control pills, ethinyl estradiol, has a stronger effect on these clotting proteins than natural estradiol.10PubMed. Hormonal contraception and thrombosis Pregnancy itself creates a similar prothrombotic shift, which is why clot risk rises during pregnancy and the weeks after delivery. Hormone replacement therapy in menopause can do the same, though the degree of risk depends on the formulation and route of delivery.
Immobility and Lifestyle Triggers
Sitting still for long stretches, whether on a transatlantic flight, during a hospital stay, or at a desk, slows blood flow through the deep veins of the legs. For people who already carry other risk factors, this stasis can tip the balance toward clot formation. Preventive strategies for long-haul travel include wearing compression stockings, doing leg exercises, staying hydrated, and, for those at high risk, prophylactic blood thinners before the flight.11PubMed. Fright of Long-Haul Flights: Focus on Travel-Associated Thrombosis Surgery, particularly hip and knee replacements, is another common trigger because it combines tissue injury, inflammation, and days of reduced mobility.
Your Body Clock Plays a Role
A less obvious factor is time of day. Your body’s internal clock regulates the rhythmic production of clotting factors and the activity of the system that breaks clots down. Research shows that core clock genes orchestrate a daily rise and fall in clotting tendency, including time-of-day changes in a substance that inhibits clot breakdown. Disruptions to this rhythm, from shift work, irregular sleep, or altered light exposure, can create a persistently clot-prone state.12Research and Practice in Thrombosis and Haemostasis. Circadian clock regulation of hemostasis: a systematic review of molecular pathways This may partly explain why heart attacks and strokes cluster in the morning hours, when clotting activity naturally peaks.
Symptoms to Watch For
The warning signs of a blood clot depend on where it forms. The two most common dangerous locations are the deep veins of the legs (deep vein thrombosis, or DVT) and the lungs (pulmonary embolism, or PE).
A DVT in the leg often shows up as swelling, pain, warmth, and redness in one calf or thigh. The discomfort tends to worsen when you stand or walk and eases when you elevate the leg.13JAMA Network (Archives of Internal Medicine). Relationship Between Deep Venous Thrombosis and the Postthrombotic Syndrome Some DVTs produce no symptoms at all, which is part of what makes them dangerous. The silent clot can break free and travel to the lungs without warning.
A pulmonary embolism is the more immediately life-threatening event. Symptoms include sudden shortness of breath, chest pain that may worsen with deep breathing, a rapid heart rate, and sometimes coughing up blood.14PubMed. Clinical presentation of deep vein thrombosis and pulmonary embolism A large PE can cause sudden cardiovascular collapse. Any combination of unexplained breathlessness with chest pain and a fast heartbeat warrants emergency evaluation.
Clots in other locations produce their own distinct symptoms. A clot blocking an artery in the brain causes stroke symptoms: sudden facial drooping, arm weakness, and slurred speech. A clot in a coronary artery causes the crushing chest pain of a heart attack. Abdominal vein clots can cause intense belly pain and bloating.
How Blood Clots Are Diagnosed
Doctors typically start with a clinical assessment that scores the likelihood of a clot based on symptoms, medical history, and physical exam findings. For suspected DVT, a common next step is a blood test called D-dimer, which detects fragments of broken-down fibrin. A negative D-dimer in a low-risk patient can effectively rule out DVT without the need for imaging. A recent study found that tailoring D-dimer thresholds to the patient’s clinical probability safely reduced the number of ultrasound scans needed by nearly half compared to the traditional testing approach.15PubMed Central. Diagnosis of deep vein thrombosis with D-dimer adjusted to clinical probability: prospective diagnostic management study
When the D-dimer is elevated or the clinical suspicion is high, imaging confirms the diagnosis. For DVT, compression ultrasound of the affected leg is the standard tool. For pulmonary embolism, CT pulmonary angiography is the first-choice imaging technique and is excellent at both detecting and ruling out clots in the lung vessels.16PubMed Central. The role of computed tomography in the diagnosis of acute and chronic pulmonary embolism The D-dimer test has one important limitation: it rises in many conditions besides clots, including infection, surgery, pregnancy, and cancer. A positive result does not prove a clot exists; it simply means imaging is warranted.
Treatment Options
Treatment depends on the type, location, and severity of the clot, but almost every approach falls into one of three categories: thinning the blood to prevent the clot from growing, dissolving the clot chemically, or removing it physically.
Anticoagulants
Blood thinners are the backbone of clot treatment and prevention. For decades, warfarin was the standard oral anticoagulant. It works well but requires frequent blood monitoring and interacts with many foods and drugs. Newer direct oral anticoagulants (DOACs) have largely replaced warfarin for most patients. In large pooled analyses, standard-dose DOACs lowered the risk of stroke or systemic embolism by roughly 20 percent compared with warfarin and cut the risk of bleeding inside the skull by more than half.17PubMed Central. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex These advantages held regardless of how well warfarin was managed.18PubMed. Meta-Analysis of Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin According to Time in Therapeutic Range in Atrial Fibrillation The same pattern appears in frail and elderly patients, where DOACs also reduced stroke, death, and major bleeding compared with warfarin.19PubMed Central. Effectiveness and Safety of DOACs vs. Warfarin in Patients With Atrial Fibrillation and Frailty: A Systematic Review and Meta-Analysis
DOACs do still carry a bleeding risk, and they are not right for everyone. Patients with mechanical heart valves or advanced kidney disease, for instance, still typically need warfarin. Injectable blood thinners like heparin are often used in the hospital setting for immediate clot management, with oral therapy taking over for longer-term treatment.
Clot-Dissolving Drugs
When a clot threatens immediate organ damage, such as a stroke caused by a blocked brain artery, doctors may use thrombolytic drugs that break fibrin apart directly. Tissue plasminogen activator (tPA) given intravenously is the standard clot-dissolving drug for acute ischemic stroke, but it must be administered within a strict time window and only after careful screening to minimize the risk of dangerous bleeding.20PubMed. Management of acute ischemic stroke. What is the role of tPA and antithrombotic agents? For massive pulmonary embolisms that destabilize the heart, thrombolytics can be lifesaving. For deep vein clots that are extensive and threatening limb viability, catheter-directed thrombolysis delivers the drug straight into the clot through a thin tube, which concentrates the effect and may reduce systemic bleeding risk.21PubMed Central. A Case Series of Catheter-Directed Thrombolysis With Mechanical Thrombectomy for Treating Severe Deep Vein Thrombosis
Mechanical Removal
In some situations, the clot is physically pulled or suctioned out. Mechanical thrombectomy is now standard care for strokes caused by large-vessel blockages in the brain, particularly when the clot is too large or too far along for tPA alone to handle.22PubMed Central. A review of mechanical thrombectomy techniques for acute ischemic stroke The procedure involves threading a catheter from a groin artery up into the brain, where a stent-like device captures the clot and retrieves it. Similar catheter-based techniques are used for massive DVTs and certain pulmonary embolisms. In extreme cases where a pulmonary embolism is immediately life-threatening and catheter approaches are unavailable, open surgery to remove the clot (surgical embolectomy) remains an option.
Post-Thrombotic Syndrome
Even after a DVT is treated and the acute danger passes, the story is not always over. Somewhere between 20 and 50 percent of DVT patients develop post-thrombotic syndrome, a chronic condition in which the affected leg remains swollen, achy, and prone to skin changes. In 5 to 10 percent of cases, severe forms develop, including open sores on the skin that are slow to heal.23PubMed Central. The post-thrombotic syndrome Symptoms include heaviness, cramping, itching, and visible changes like darkened skin pigmentation and small surface veins that appear as the body tries to reroute blood around damaged valves.13JAMA Network (Archives of Internal Medicine). Relationship Between Deep Venous Thrombosis and the Postthrombotic Syndrome Walking and standing tend to make things worse; resting with the leg elevated brings relief.
Post-thrombotic syndrome happens because the original clot damages the delicate one-way valves inside the vein. When those valves no longer close properly, blood pools in the lower leg instead of flowing efficiently back to the heart. Compression stockings, regular walking, and leg elevation are the mainstays of managing it, though evidence on whether wearing compression stockings right after a DVT prevents the syndrome from developing in the first place has been mixed.
When Inflammation and Clotting Collide
One of the more revealing developments in clot science is the recognition that the immune system and the clotting system are deeply intertwined. When your body fights an infection, immune cells like neutrophils and monocytes do not just kill pathogens; they also release substances that activate clotting. In a controlled setting, this “immunothrombosis” helps wall off invading microorganisms inside tiny clots, limiting the spread of infection.24PubMed Central. Thromboinflammation vs. immunothrombosis: strategies for overcoming anticoagulant resistance in COVID-19 and other hyperinflammatory diseases. Is ROTEM helpful or not?
When the immune response spirals out of control, however, the clotting side spirals with it. Severe COVID-19 provided a vivid example: patients developed widespread micro-clots in the lungs and other organs, driven by a flood of inflammatory signals that activated clotting throughout the body. Standard blood thinners sometimes proved insufficient because the clotting was not just a cascade-chemistry problem; it was being continually restoked by the immune system. This intersection of inflammation and thrombosis is now an active area of research, with implications well beyond COVID for conditions like sepsis and autoimmune diseases.
May-Thurner Syndrome and Anatomical Clot Risk
Not every clot risk factor shows up on a blood test. Some people carry structural quirks in their anatomy that predispose them to clots in specific locations. May-Thurner syndrome is a prime example. In this condition, the right common iliac artery crosses over and compresses the left common iliac vein against the spine, restricting blood flow out of the left leg.25PubMed Central. May-Thurner syndrome: a not so uncommon cause of a common condition The chronic compression irritates the vein wall and slows flow, setting up two of Virchow’s three conditions for clotting.
May-Thurner syndrome is underdiagnosed because the compression often produces no symptoms until a clot suddenly forms, and standard leg ultrasounds can miss it. It tends to affect younger women more than other groups and should be considered whenever a DVT appears in the left leg of a patient without obvious risk factors.26PubMed. May-Thurner syndrome: History of understanding and need for defining population prevalence Treatment often involves stenting the compressed vein open in addition to standard anticoagulation, because blood thinners alone do not fix the underlying mechanical problem. This is a good reminder that when a clot seems to come out of nowhere, an anatomical cause is worth investigating.